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Abstract
Background: Long-term use of opioid analgesics (OA) for chronic pain may result in opioid use disorder (OUD).
This is associated with adverse outcomes for individuals, families and society. Treatment needs of people with OUD
related to chronic pain are different compared to dependence related to use, and also injection, of illicit opioids. In
Nordic countries, day-to-day practical advice to assist clinical decision-making is insufficient.
Aim: To develop principles based on expert clinical insights for treatment of OUD related to the long-term use of
OA in the context of chronic pain.
Methods: Current status including an assessment of barriers to effective treatment in Finland, Denmark, Iceland,
Norway, Sweden was defined using a patient pathway model. Evidence to describe best practice was identified
from published literature, clinical guidelines and expert recommendations from practice experience.
Results: Availability of national treatment guidelines for OUD related to chronic pain is limited across the Nordics.
Important barriers to effective care identified: patients unlikely to present for help, healthcare system set up limits
success, diagnosis tools not used, referral pathways unclear and treatment choices not elucidated. Principles include
the development of a specific treatment pathway, awareness/ education programs for teams in primary care,
guidance on use of diagnostic tools and a flexible treatment plan to encourage best practice in referral, treatment
assessment, choice and ongoing management via an integrated care pathway. Healthcare systems and registries in
Nordic countries offer an opportunity to further research and identify population risks and solutions.
Conclusions: There is an opportunity to improve outcomes for patients with OUD related to chronic pain by
developing and introducing care pathways tailored to specific needs of the population.
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Background
The long-term use of opioid analgesics (OA) in the con-
text of chronic pain syndromes may result in opioid use
disorder (OUD) [1]. This is associated with harm to indi-
viduals, their families and also to society [2]. OUD in
this population ranges from mild disease with few
criteria of OUD fulfilled to severe and represents a
heterogeneous population [3]. For the patient, each dose
will provide some immediate relief, but repeated use of
opioids can worsen pain, and associated psychological
symptoms. Dependence, when established, interacts with
pain and associated symptoms such as sleep-disturbance,
psychological distress, tiredness and cognitive symptoms.
This may result in a perceived need for opioids or other
medication for control of such symptoms [4]. Chronic
pain may alone interfere severely with the ability to par-
ticipate in work and social life; the impact of long-term
opioid therapy at the individual level is unclear.
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Long-term opioid therapy, often considered in excess of
3 months [5, 6], has a dose-dependent relation to the
development of OUD and consistent use of high doses
may indicate risk of the problem [7].
Without intervention, OUD commonly results in ser-
ious psychosocial issues, medical problems and a signifi-
cant risk from overdose [8]. Pharmacological choices
indicated for the treatment of OUD in this population in-
clude tapering of OA or maintenance therapy with opioid
agonist therapy (OAT) such as buprenorphine/ naloxone
or buprenorphine [9, 10] and methadone [11, 12].
Prescription of OAT for OUD must be considered as
distinct from use of opioids for pain, even though prod-
ucts may have use in both situations.
It is recognised that the characteristics [13], behav-
iours [14] and needs [15] of patients with OUD related
to chronic pain are often different when compared to
patients with dependence related to use and also injec-
tion of illicit opioids [12]. OUD may often be in the con-
text of the use of many sources and types of opioid
especially when severe, however when related to chronic
pain distinct features are present. Problems such as
social disadvantage, contact with the criminal justice
system, and co-existent health problems may be less
common in those with OUD related to chronic pain and
prescribed OA [12], especially during early phases of the
problem. Illicit heroin is now not the only source of
opioid and in some countries, is not the major problem:
OA may make up a large proportion of the opioid prob-
lem whether prescribed, illicit or obtained from family
or other contacts [16]. These differences point to the
potential for early intervention and the need for a
specific treatment approach tailored to the requirements
of this population [12].
Countries have published guidelines for the use of OA
in relation to chronic pain (e.g. USA [17], UK [18],
Australia [19]) and for the management of OUD in gen-
eral [20]. Specific guidance for OUD related to chronic
pain is only available in a limited number of countries (e.g.
UK [21], Spain [22], Australia [23]) and does not aid the
set-up of care services or support practical, day-to-day
decisions in management: the problem has not been ad-
dressed optimally in any country so far. In the Nordics
common approaches to the management of OUD and
access to healthcare is an opportunity to assess clinical
practice. This work aims to assess current approaches,
limits and successes for care of patients with OUD related
to chronic pain and, based on this analysis, outline princi-
ples for policy and practice development in the Nordic
countries to improve outcomes for patients [12].
Method
A structured approach to collect evidence and assess
clinical practice in OUD related to chronic pain was
defined based on a patient journey model describing
care in a series of steps from patient initial engagement,
through diagnosis to treatment. The patient journey
model was defined by the authors based on their experi-
ence and with reference to other similar examples [24].
Sources describing clinical practice, such as national
OUD and pain management guidelines, were identified
by experts in relevant fields and collected. Data from
sources were extracted and assessed by two reviewers
familiar with analysis and the therapy area. Based on the
results, a consensus on principles for clinical care to
improve outcomes and future research were developed.
Results
Care was assessed in Denmark, Finland, Iceland, Norway
and Sweden. National treatment guidelines for the use
of OA (e.g. in patients with chronic non-cancer pain or
acute post-surgery treatment) were identified from pro-
fessional societies or bodies responsible at national level
for care, in Norway [25], Finland [26], Denmark [27],
and Sweden [28]. National or similar guidelines for the
management of OUD care in general were identified in
Denmark [29], Finland [30], Norway [31], Sweden [32]
and Iceland [33]. Specific guidance on the treatment of
OUD related to chronic pain was identified in Sweden
[32]. Limits to effective care were identified and are de-
scribed according to the patient journey model (Fig. 1).
Structured assessment of the limits to successful care:
(1) Engagement
Patients or users of OA often do not engage with
healthcare services to seek help for OUD related to
chronic pain. This is due to a lack of awareness of
the potential problems of long-term opioid therapy
aiming to reduce symptoms associated with chronic
pain from both patients and prescribing doctors,
limited knowledge on the benefits of treatment, and
limited engagement with the addiction services,
which provide care mainly for patients with
problems related to injection of illicit opioids and/
or psychoactive drugs, due to fear or stigma.
Advocacy from healthcare professionals (HCP) in
primary care (PC) and other settings may be
insufficient in many cases, reducing the chance of
patients agreeing to further steps towards diagnosis,
referral and treatment. This lack of advocacy is
often related to a low level of knowledge in PC of
OUD in general and options for care specifically
related to OUD and chronic pain.
(2) Diagnosis in PC and addiction specialist settings is
not optimal.
Physicians, nurses and other HCP often have little
training in the recognition and treatment of OUD.
A lack of familiarity with appropriate diagnostic
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tools limits ability to effectively define patient
problems and progress to appropriate care.
Diagnosis may be difficult; for some patients it may
be a challenge to accept that OUD is present,
especially because the source of the dependence –
OA pain medication – was prescribed and provided
from within the medical system and is taken to
reduce symptoms. Some pain relief is recognised
upon taking the medication by the patient but less
is recognised of side-effects such as the risk in escal-
ating doses, developing dependence, cognitive
impairment, gastrointestinal symptoms or other
symptoms caused by opioids. Patients may avoid
diagnosis despite evident problems due to a fear of
attracting stigma when entering the conventional
OUD treatment pathway.
(3) Referral pathways are poorly defined or are
inadequate.
This limits the potential for progress with effective
management. Care services developed for the
management of addiction, related commonly to
illicit opioid or drug use, often do not meet the
needs of this specific population. The stigma
associated with using existing, conventional
treatment services limits participation of many
patients after referral. HCP may be unaware of the
risk of progression from OA use related to chronic
pain to other forms of opioids and the risk of harm
associated – limiting the urgency of referral.
(4) Treatment assessment must be based on a full
clinical picture and understanding of the needs of
the patient.
The goal of early intervention is important to
prevent the gradual worsening of OUD and
associated comorbidities over time. The difficulty in
establishing a detailed clinical picture for each
individual patient, including OUD, pain, psychiatric
comorbidity (anxiety disorders and depression), and
also in building relationships with patients due to
limited engagement and inappropriate treatment
service set-up often complicate adequate assess-
ment. Success in treatment is limited due to lack of
an integrated and holistic approach to care. Across
the range of stakeholders who provide the necessary
parts of care, a lack or insufficient awareness of the
specific and different nature of treatment for OUD
related to chronic pain make it hard to deliver an
integrated program required for success.
(5) Treatment success is limited if the approach is not
specific to the needs of patients with OUD related
to chronic pain.
Treatment must be based on a holistic approach
and individual needs. The chronic pain patients seek
relief from is difficult to treat in terms of reduced
pain independent of given treatment. When
tapering of opioids HCP should consider the
potential of opioids to induce hyperalgesia and the
possible outcome of, in a part of the population,
Fig. 1 Current status of treatment, policy & practice. Treatment of OUD related to long-term opioid analgesic use and chronic pain
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worsening pain and function in daily life. Many
stakeholders are required for effective care and
outcomes are not optimal if clinical services are not
integrated and aligned. Inappropriate treatment
choices regarding medication, duration and therapy
may result from inexperience or uninformed
decisions. Guidelines do not provide information to
assist clinicians in the practicalities of building and
delivering a treatment plan by means of an
integrated team specialized in this particular setting.
Functions including medical treatment,
psychological and social therapy must be aligned for
success – a lack of awareness and experience in
treating patients in this population makes this more
difficult to achieve. Disjointed management across
different healthcare functions may lead to
inadequate service delivery and poor outcomes.
Overall the lack of understanding of the size and na-
ture of the epidemiology of OUD related to chronic pain
limits the development and provision of care services. In
policy, at national and regional level, there is often a lack
of clarity on the commitment to provide appropriate
resources to ensure the identification and treatment of
OUD related to chronic pain.
Discussion
There is potential to improve the approach for the man-
agement of OUD related to chronic pain. Current policy
and practice does not reflect the specific needs of pa-
tients and available guidance does not provide sufficient
direction on the practicalities of care overall. Guidance
for clinical practice in pain management and/or OUD
care may not be sufficiently useful beyond providing
general information; it is recommended that such policy
and guidance is developed further to meet the needs of
the patients considering the comorbidity and challenges
of treatment of this group. In relation to this, principles
for best practice care of people with OUD related to
chronic pain are described according to a patient jour-
ney model (Fig. 2).
Increase engagement
Presentation and engagement with care – the starting
point for treatment – can be made easier and more
accessible. Awareness, advocacy and risk-based reviews
of treatment are needed in services that are perceived as
attractive, relevant and are specifically designed for the
patient population [34].
1. In PC and with specialists in addiction medicine,
provide educational programs aimed at increasing
advocacy by building awareness of the problem,
knowledge of referral pathways and successful
interventions [35, 36].
2. Consider prescription data reviews to identify
patients at risk, with a potential need for help, as in
other locations including: Europe [37], UK [12],
Denmark [38], US [36], Australia [23, 39].
3. Develop simple decision-support tools to help pre-
scribers of OA, pharmacists and others to target,
plan and hold discussions with patients about de-
pendence problems, referral and treatment options
[36, 39].
4. Set up and support the use of digital and other
easy-to-access, publicly available tools (digital
Fig. 2 Suggested treatment approach, OUD related to chronic pain
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applications to self-assess, telephone and web help-
line/ chat websites) to provide support and trusted
resources for patients, carers, and family members
[36, 40].
Improve diagnosis
The gap in diagnosis and referral limits uptake of suc-
cessful interventions and is based on limited awareness
of proven tools and successful pathways to treatment.
1. Provide specific training for HCP in PC to improve
skills and knowledge of diagnosis and referral
pathways. Addiction and pain management
specialists and national authorities should
collaborate in providing educational pathways for
HCP and psychiatrists. This includes drug screening
and detection of relevant behavioural changes such
as using opioids for reasons other than pain, to “get
high” or “manage stress” [41], rapidly escalating
demands for dose increases, unusual increase in
doses, observed or reported intoxication or
unexplained withdrawal symptoms, repeatedly
reporting that opioid medication was lost, stolen, or
destroyed; injection of opioids; threatening or
harassing staff; repeatedly seeking prescriptions
from other providers or emergency rooms;
alteration, borrowing, stealing or selling
prescriptions [42]; poor attendance at treatment
review; appearing sedated at times; resisting drug
screening; and deteriorating social function [21].
Education on modern diagnostic tools [36, 43, 44],
access to training resources [45], practical
guidelines for diagnosis [46] is recommended.
Diagnostic and screening tools include those
specific to OA or chronic pain (Current Opioid
Misuse Measure [47], Prescription Opioid Misuse
Index [44]). General tools may also be useful,
including Leeds Dependence Questionnaire (LDQ)
[48], Diagnostic and Statistical Manual of Mental
Disorders, (DSM-5) [49], and International
Statistical Classification of Diseases and Related
Health Problems 10th Revision (ICD-10) [50].
2. Provide resources to set up and encourage the
development of clinical practice aiming to achieve
diagnosis in a joint effort between pain
management specialists, addiction specialists and
PC [46]. The model of care may be different in each
location but the aim is co-operation with joint
goals, plans and coordinated delivery of care with
measurement of outcomes supported by patient
registries. The ideal model of care presents a dedi-
cated service for patients based on organisation of
resources from PC, pain and addiction services.
3. Provide tools to assist HCP in working with
patients to agree a “contract” defining goals of
treatment and prescription renewal. If this contract
cannot be maintained, this may be a point of
acceptance of the need for help. Experience with a
trial of tapering of prescribed opioids, performed in
cooperation with the patient, is an important step
in diagnosis; a lack of progress in dose tapering may
indicate OUD.
Increase the chance of successful referral to specialist
care
Referrals to specialist care are limited because of unclear
or inappropriate pathways.
1. Ensure at policy and clinical practice level that
there is a referral pathway appropriate to the needs
of patients with an option, when practical, to offer
initial specialist consultation in PC to reduce stigma
[40]. Patient with OUD related to chronic pain are
more likely to engage, and be retained, in treatment
if care pathways are provided that are distinct to
the services offered to persons with OUD related to
use and injection of illicit opioids [12, 51].
Improve treatment assessment and choices
Non-optimal treatment assessment and choices of treat-
ment may result from inexperience of HCP.
1. A specific clinical assessment is recommended for
patients with OUD related to chronic pain [21, 46,
52]. A detailed profile or treatment inventory is
required with status (e.g. pain, mental health status,
anxiety, depression, other psychiatric disorders),
severity of dependence and identification of other
substances in use (non-opioid medications with
addictive potential such as benzodiazepines,
stimulants, alcohol/ nicotine and other substances).
A pain assessment is required; if pain is a dominant
feature, management led by pain specialists may be
recommended. A biopsychosocial approach is useful
in pain investigation to understand how pain
interferes with life and to understand how long-
term opioid use may contribute to suffering at indi-
vidual level. Many tools to assess pain may be used:
The Brief Pain Inventory (BPI) [53], The Client
Health Questionnaire (PHQ-9) [54], EQ-5D-5 L
[55] or a composition of tools as in Swedish Quality
Registry for Pain Rehabilitation [56]. For patients
with co-existing mental health problems, plans
should be made to manage these issues. Severity of
dependence guides decision-making and is the key
for treatment assessment. Patients with severe prob-
lems may require higher doses of medication or
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need longer to achieve recovery. This may be assessed
with tools such as DSM-5 [49] or ICD-10 [50].
2. A joint individualised [52, 57] treatment plan
integrated across addiction services, pain clinics,
psychiatry and PC services with a long-term view
on care is required [46].
3. Management of existing OA medications for
chronic pain and planning to reduce or taper
medications over time in agreement with the
patient [46]. Tapering can be performed with the
prescribed drug or a switch to buprenorphine/
naloxone [58]. It may be possible to stop opioid
medications and use adjunctive medication to
support those agreeing to this plan, and not
displaying signs of psychological dependence.
4. Treatment choices start with a managed reduction/
tapering of current OA, which can be tried either as
a slow tapering in an outpatient setting, or faster in
an inpatient setting. If these options are not
successful, treatment with opioid agonist therapy
(OAT) as part of an integrated psychosocial care
program may be required [39, 46, 52]. Treatment
should be planned on the basis of a detailed patient
assessment or “inventory” [46, 52].
5. Treatment with OAT may be recommended if dose
reduction/ tapering does not lead to improvement
and OUD is considered to be moderate to severe.
Based on the patient inventory including full listing
of prescription and other drugs in use by the
patient, a single dose of one opioid agonist can be
prescribed. Commonly prescribed options include
buprenorphine/ naloxone (as recommended in
specific, existing national guidelines in Sweden),
methadone or buprenorphine [52]. The decision to
use OAT, and the exact treatment plan including
choice of medication, is based on clinical scenario,
risk profile, social & family situation, patient
preference and assessment of safety and risk factors
such as misuse, diversion, risk at home, concurrent
addictive behaviour to other substances (e.g. alcohol
or benzodiazepines), previous overdoses, psychiatric
comorbidity [46].
6. Buprenorphine/ naloxone is a common initial
recommendation if OAT medication is considered,
in alignment with guidance [32]. Buprenorphine,
because of potential for diversion, and methadone,
due its profile with side effects including sedation
and risk of overdose [45], may commonly be less
attractive starting choices. No one choice of
medical therapy is suitable for all patients; it is
important to tailor therapy based on the needs of
the individuals [52].
7. Intensive treatment monitoring is needed as
standard [21], especially at the beginning of
treatment programs [52] and strategies to respond
in the event of relapse should be in place.
8. Adjustments of dose and choice of programs for
psychosocial support may be necessary; decisions
are guided by clinical progress including factors
such as use of other opioids or addictive substances,
craving and potentially other psychiatric symptoms
such as anxiety or depression.
9. Cessation of OAT is guided by clinical response;
many patients are expected to complete therapy
and cease using any opioids. Duration of therapy
may extend beyond 1 year [21]. Therapy should not
be stopped prematurely and against the patient's
will; therapy discontinuation should be carefully
planned in discussion with patients and HCP
jointly.
10. Access to appropriate specialist support groups
specific to OUD and chronic pain problems for
patients and their families should be available and
actively referred to, for example behavioural therapy
[12]. Therapy focused on acceptance of the problem
is also recommended; this may include mindfulness
coaching. Special education about the nature of
chronic pain and support for patients is important;
catastrophizing thoughts about the severity of pain
and problems in relation to changing analgesic
mediations are common in many patients. It is
important to address this issue as it may be
possible, at least in some part, to address it with
education and development of coping strategies.
This analysis focuses on the steps of care specific to
OUD related to chronic pain; it is important to also act
to prevent problems emerging. It is important that all
patients with chronic pain receive appropriate care.
Where treatment with OA is considered, screening for
risk of substance use disorder (SUD) in general is
important in the evaluation of medication treatment of
pain. Prescribing OA needs special attention for people
at risk for SUD and special precautions are needed if
OA are necessary. OA prescription practice should be
well-founded to ensure appropriate pain care is provided
for chronic pain patients – this in turn will limit initi-
ation of large scale harmful opioid use. Early interven-
tion is needed to avoid treatment with OA for pain
developing into chronic OUD. An integrated and multi-
disciplinary service should be provided for all patients
who develop OUD in relation to chronic pain. It is
important to set up an environment in which there is an
ongoing recognition of the specific needs of populations
with OUD related to chronic pain, to design care ser-
vices to meet the needs of these groups and to support
HCP and other services in providing integrated and indi-
vidualised care. It is important to define the ideal care
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set up at community and specialist levels, with goals of
initial, short and longer-term treatment. In the
longer-term perspective education to reduce the impact
of stigma and related barriers to treatment may be valu-
able: starting with practical treatment steps can also be a
part of changing this.
This work is based on an assessment of current
approaches to OUD care in chronic pain setting with in-
sights from specialists each with at least 10 years’ experi-
ence in OUD (10) and pain management (1); there can
be benefit in including other pain specialists and organi-
sations. This work is based on review of evidence from
Nordic countries; this may limit wider applicability but
the challenges and principles for managing OUD related
to chronic pain identified here likely do however apply
more widely. The existence of health registries and the
similar approaches to OUD management and healthcare
in general in Nordic countries present an opportunity to
collect evidence to define the magnitude of the problem
in greater detail, for example by assessing OA prescrip-
tion data, and to develop further evidence-based
approaches to clinical practice.
Conclusion
The population with OUD related to chronic pain may
be underserved for healthcare and find it hard to access
therapy matched to their specific needs; there is an op-
portunity to improve the outcomes of treatment in these
populations with specific care pathways. Principles for
managing this complex problem are recommended here
based on a consensus of clinical experience. Clinical
practice experience highlights the need for policy change
and specific practice development to make it possible to
address the needs of this population; this includes the
development of specific tailored care pathways. There is
a need also to plan for research based on the opportun-
ity in the region, provided by integrated health registries
and common approaches to care, to define with
increased resolution population needs and to confirm
evidence supporting specific interventions. This is a call
to action for health services and research organisations
to act to improve outcomes for many with chronic pain
and OUD.
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